Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein

Arthritis and Rheumatism

Volumn 52, Issue 2, 2005, Pages 642-650

  Rodriguez, Wilfredo ^a   Mold, Carolyn ^a   Kataranovski, Milena ^a   Hutt, Julie ^b   Marnell, Lorraine L ^a   Du Clos, Terry W ^a,c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; DNA ANTIBODY; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLOMERULUS BASEMENT MEMBRANE; IMMUNE COMPLEX NEPHRITIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; C-REACTIVE PROTEIN; DNA; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-10; KIDNEY GLOMERULUS; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; PROTEINURIA;

EID: 13444306169     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20846     Document Type: Article

References (42)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 87-96.
2. Gescuk BD, Davis JC Jr. Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 2002;14:515-21.
3. Karpouzas GA, Hahn BH. Systemic lupus erythematosus. In: Smolen JS, Lipsky PE, editors. Targeted therapies in rheumatology. London: Martin Dunitz; 2003. p. 563-81.
4. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-4.
5. Carroll MC. A protective role for innate immunity in autoimmune disease. Clin Immunol 2000;95:S30-8.
6. Walport MJ. Lupus, DNase and defective disposal of cellular debris. Nat Genet 2000;25:135-6.
7. Du Clos TW. C-reactive protein as a regulator of autoimmunity and inflammation [editorial]. Arthritis Rheum 2003;48:1475-7.
8. Du Clos TW. Function of C-reactive protein. Ann Med 2000;32:274-8.
9. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-97.
10. Du Clos TW. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol 1989;143:2553-9.
11. Robey FA, Jones KD, Tanaka T, Liu TY. Binding of C-reactive protein to chromatin and nucleosome core particles: a possible physiological role of C-reactive protein. J Biol Chem 1984;259:7311-6.
12. Kaplan MH, Volanakis JE. Interactions of C-reactive protein with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112:2135-47.
13. Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to FcγRI in transfected COS cells. J Immunol 1995;155:2185-93.
14. Stein MP, Mold C, Du Clos TW. C-reactive protein binding to murine leukocytes requires Fcγ receptors. J Immunol 2000;164:1514-20.
15. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is Fcγ receptor II. J Exp Med 1999;190:585-90.
16. Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad U S A 1997;94:2575-80.
17. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-reactive protein mediates protection from lipopolysaccharide through interactions with FcγR. J Immunol 2002;169:7019-25.
18. Heuertz RM, Dongyuan X, Samols D, Webster RO. Inhibition of C5a des Arg-induced neutrophil alveolitis in transgenic mice expressing C-reactive protein. Am J Physiol 1994;266:L649-54.
19. 1 mice treated with C-reactive protein. Clin Immunol Immunopathol 1994;70:22-7.
20. 1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 2003;48:1602-11.
21. Wakayama H, Hasegawa Y, Kawabe T, Hara T, Matsuo S, Mizuno M, et al. Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcR γ-deficient mice. Eur J Immunol 2002;30:1182-90.
22. Rubin RL. Enzyme-linked immunosorbent assay for anti-DNA and antihistone antibodies. In: Rose NR, Friedman H, Fahey JL, editors. Manual of clinical laboratory immunology. Washington: ASM; 1986. p. 744-9.
23. Du Clos TW, Rubin RL, Tan EM. Monoclonal antibody for DNA measurement in biological fluids. J Immunol Methods 1986;88:185-92.
24. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-391.
25. Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003;171:6323-7.
26. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
27. Baltz ML, Rowe IF, Pepys MB. In vivo turnover studies of C-reactive protein. Clin Exp Immunol 1985;59:243-50.
28. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-63.
29. Burlingame RW, Volzer MA, Harris J, Du Clos TW. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 1996;156:4783-8.
30. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcγ receptors. J Autoimmun 2002;19:147-54.
31. Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999;5:694-7.
32. Szalai AJ, Nataf S, Hu XZ, Barnum SR. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 2002;168:5792-7.
33. Pepys MB, Lanham JG, de Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982;8:91-103.
34. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus: an indicator of disease activity? Clin Exp Immunol 1992;90:106-10.
35. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004;13:137-47.
36. Tarzi RM, Davies KA, Claassens JW, Verbeek JS, Walport MJ, Cook HT. Both Fcγ receptor I and Fcγ receptor III mediate disease in accelerated nephrotoxic nephritis. Am J Pathol 2003;162:1677-83.
37. Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, Robert ME, et al. IL-10 regulates murine lupus. J Immunol 2002;169:2148-55.
38. Kitching AR, Tipping PG, Huang XR, Mutch DA, Holdsworth SR. Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice. Kidney Int 1997;52:52-9.
39. Kitching AR, Tipping PG, Timoshanko JR, Holdsworth SR. Endogenous interleukin-10 regulates Th1 responses that induce crescentic glomerulonephritis. Kidney Int 2000;57:518-25.
40. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR. Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 1997;27:530-7.
41. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6.
42. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42.